Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Docetaxel in metastatic or recurrent HNSCC
NCT00485485Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib and docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 12 weeks. Started Jan 2007; status: completed.
02
Drugs
imatinibdocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00485485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485485.